Whitehawk Therapeutics Business Summary

Whitehawk Therapeutics, Inc. (WHWK) is a clinical-stage oncology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for difficult-to-treat solid tumors. Following its 2025 strategic pivot and rebranding from Aadi Bioscience, the company generates capital through a combination of asset divestitures, such as the $102.4 million sale of its legacy FYARRO business to Kaken Pharmaceutical, and private investment in public equity (PIPE) financing. Its primary business segments are defined by its three-asset ADC portfolio in-licensed from WuXi Biologics: HWK-007 (targeting PTK7), HWK-016 (targeting MUC16), and HWK-206 (targeting SEZ6). Whitehawk competes directly with ADC developers like Day One Biopharmaceuticals, Kelun-Biotech, Genmab, and Mersana Therapeutics, positioning itself as a "next-wave" innovator by utilizing a proprietary Topoisomerase I inhibitor payload and highly stable cleavable linkers to achieve a superior therapeutic index compared to first-generation predecessors. Leadership is spearheaded by President and CEO David Lennon, Ph.D., a 20-year industry veteran who previously served as CEO of Satellite Bio and held senior executive roles at Novartis. The company was founded by Neil Desai, Ph.D., the former Senior VP of R&D at Abraxis BioScience and architect of the nanoparticle technology behind Abraxane and FYARRO. The executive team includes CFO Scott Giacobello, formerly of GW Pharmaceuticals, and Chief Medical Officer Margaret Dugan, MD, who brings deep oncology expertise from Novartis and Merck. Whitehawk is backed by a high-pedigree investor base including Orbimed Advisors, Satter Investment Management, and Novartis Bioventures, with a board of directors that features notable industry figures such as Caley Castelein and Baiteng Zhao, the co-founder of ProfoundBio.